Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

2 Specialized Healthcare Companies With Great Return Potential: Gilead Sciences, Inc. (GILD) and More

Page 1 of 2

There are many healthcare stocks traded on the market that an investor can choose from. I’ve seen numerous articles that claim that many healthcare stocks are good investments because they will greatly benefit from “Obamacare” or because of the aging American population, and/or numerous other reasons. When looking at the healthcare sector, there’s “big pharma” to invest in. The makers of medical devices are another option. Drugstores are yet another choice as an investment in healthcare. Here are 2 unique healthcare stocks, however, that are helping to make the lives of those with incurable diseases or conditions better.

Gilead Sciences, Inc. (NASDAQ:GILD)HIV and hepatitis C– incurable but manageable?

Gilead Sciences, Inc. (NASDAQ:GILD) is the world’s largest producer of HIV drugs. Thanks to this company, those with this disease are able to manage it much better. Sales of these drugs also rose in the company’s most recent quarter as well, as they beat expectations on both their top and bottom lines. Gilead is also experimenting with a hepatitis C drug, which if approved, could give the company another source of explosive growth. According to Michael Yee of RBC capital Markets (as cited by Bloomberg), “HIV and hepatitis C are going to lead an enormous growth phase from 2014 to 2018 [for the company]… Meanwhile, Gilead is quietly building a hematology franchise as another additional growth driver.”

Gilead, by also researching into blood cancers, is pushing forward with yet another way to make serious diseases more tolerable. Blood cancer drugs will help with the company’s growth as well. Gilead currently trades at about 25 times earnings, with a more reasonable forward P/E ratio of 15. The company also currently has 19 analysts that rate it as a buy, three rating it at a hold, and none suggesting to sell.

Other than being the leader in HIV drugs, Gilead has also acquired Pharmasset, which gives them instant access to potentially the first oral Hepatitis C drug (if approved by the FDA). Hepatitis C is expected to
to grow in the coming years, and analysts have forecasted it to generate over $20 billion in revenue, with the Credit Suisse Group estimating Gilead reaping in up to $3.8 billion in related sales by 2020. Watch Gilead’s Hep C drug Sofosbuvir closely, for it is likely to get approved and if it does– the company will see explosive growth, making today’s current share price attractively valued.

Playing the growing diabetes epidemic…

DaVita HealthCare Partners Inc (NYSE:DVA) provides kidney dialysis services for patients suffering from chronic kidney failure, or end stage renal disease (ESRD) in the United States. The company is also a favorite of Warren Buffett, who is gobbling shares up as the company continues to expand. After increasing their position by 1.3% on Jan. 9, Berkshire Hathaway Inc. (NYSE:BRK.A) became the largest owner of the dialysis giant- holding a 14.65% stake in the company. DaVita is now Berkshire’s eight largest long-term position as well, according to Forbes. Berkshire, up until December, had apparently been buying about a million shares a month.

Along with a Buffett stamp of approval, the company also has many other positives. The high growth company has increased revenue by nearly 20 percent annually over the last 10 years. The company in 2005 also created the first full-service pharmacy that directs its full attention to kidney patients. DaVita is currently priced at about 21 times earnings, with a forward P/E ratio of about 16.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!